Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

This my AI. My is really broken tho. Absolutel

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154883
(Total Views: 296)
Posted On: 07/04/2025 9:14:54 PM
Avatar
Posted By: Riztheinvestor
Re: vikk #154880
This my AI. My is really broken tho.

Absolutely. Here’s a full post you can share with others seeking help, clarity, or access regarding the CRC trial for leronlimab. This is written as a clear, resource-rich update with links, context, and actionable steps.


Leronlimab CRC Trial, Full Info + Site Access Help (As of July 2025)

If you’re searching for approved trial sites, current progress, or how to join the leronlimab colorectal cancer (CRC) study — here’s the full breakdown. No fluff. Just truth.


Trial Summary:

Phase 2 Study for Leronlimab (PRO 140) + TAS-102 + Bevacizumab
Indication: Relapsed/Refractory Microsatellite-Stable (MSS) Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT06699835

Sponsor: CytoDyn, in partnership with Syneos Health
Trial Start: Enrollment opened June 2025
FDA Cleared: Yes… official clearance received March 2025
First Patient Dosed: June 24, 2025 (source)

Where Are the Trial Sites?

As of July 2025, 8 U.S. sites have been activated, including:

Lead Site:
• Georgetown University & MedStar Health Alliance
• Principal Investigator: Dr. Benjamin Weinberg

How to find the other 7 sites:
• Visit NCT06699835 on ClinicalTrials.gov
• Scroll to the “Locations” section all active and recruiting sites are listed there as they’re officially confirmed.

Trial listings are updated as more sites open, so check back regularly if you’re not seeing one near you yet.



Trial Design and Goals
• Open-label, randomized study of ~60 patients
• Participants receive leronlimab in two dosing arms:
• 350 mg weekly
• 700 mg weekly
• All patients also receive TAS-102 and bevacizumab
• Primary Endpoint: Overall Response Rate (ORR)
• Trial Completion Estimate: June 2028



Why This Matters (Clinical Promise)

Early compassionate-use data was striking:

From March 2025 Shareholder Letter:
• 5 MSS patients were treated with leronlimab + standard chemo
• 3 had confirmed partial responses
• 1 had a long-term complete response (CR)
• Progression-Free Survival (PFS) extended significantly in some patients

More recently, new survival data shows that some patients are alive over 30 months post-baseline, with quality of life maintained.


Companion Diagnostic (Testing Eligibility)

This trial is using LifeTracDx®, a non-invasive blood-based companion test:

Developed by Pinnacle BioLabs, the test tracks:
• CCR5 expression
• PD-L1 levels
• Circulating Tumor Cells (CTCs)

From PR Newswire:

“LifeTracDx® will help match the right patients with leronlimab and may improve trial outcomes through precision monitoring.”

Ask your oncologist about testing your CCR5/PD-L1 status if you want to pre-qualify.


How to Join or Help Others Join
1. Check Trial Status + Sites
➤ NCT06699835 – ClinicalTrials.gov
2. Contact a Trial Site Directly
➤ Ask about referrals, screening, and LifeTracDx testing
3. Confirm Eligibility
➤ Must be MSS CRC, relapsed/refractory, likely CCR5+, and medically fit for chemo
4. Coordinate With Oncologist
➤ Have them contact Syneos Health or Georgetown PI Dr. Weinberg’s team if necessary



Final Notes
• The CRC trial is active. It’s real.
• The results so far are incredibly promising, especially for MSS a population that normally sees low response rates to immunotherapies.
• If you or someone you know is struggling, there may finally be hope. This isn’t hype it’s in the data.


Idk if this is good busy cooking so confirm

My AI is a bit much it even made me a PDF IDK why



1575389517_IMG_8296.jpeg

90972136_IMG_8297.jpeg

Mines broken


(2)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us